Atorvastatin 80 mg/day lowered low-density lipoprotein (LDL) cholesterol levels further than did pravastatin 40 mg/day, and it also reversed atherosclerosis as reflected by reduced carotid intima-media thickness (CIMT), according to results of a head-to-head trial published online Sept. 23 in Circulation.
“This is the first comparison of two statin drugs in a general population that looked at more than their cholesterol-lowering abilities,” lead author Allen J. Taylor, MD, director of cardiovascular research at Walter Reed Army Medical Center in Washington, D.C., says in a news release. “Previous studies found that patients in whom plaque stabilized or stopped progressing had the lowest risk of heart attacks and other cardiovascular disease problems.
In general, past studies have shown that regression [of plaque] is uncommon.” This single-center, randomized clinical trial followed 161 patients who met National Cholesterol Education Program (NCEP) II criteria for lipid-lowering therapy. Mean age was 60 years, 71.4% were male, and 46% had known cardiovascular disease. Baseline CIMT and other clinical characteristics were similar in both groups.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!